Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer

Hiroshi Kubo1*, Takashi Suzuki2, Tomoko Matsushima3, Hideki Ishihara3,7, Kazuya Uchino4, Satoshi Suzuki5, Sachiyo Tada3, Masahiro Yoshimura4 and Takashi Kondo6

Abstract

Background: Lung cancer is one of the leading causes of cancer death worldwide. Even with complete resection, the prognosis of early-stage non-small cell lung cancer is poor due to local and distant recurrence, and it remains unclear which biomarkers are clinically useful for predicting recurrence or for determining the efficacy of chemotherapy. Recently, several lines of evidence have indicated that the enzymatic activity of cyclin-dependent kinases could be a clinically relevant prognostic marker for some cancers. We investigated whether the specific activity of cyclin-dependent kinases 1 and 2 could predict recurrence or death in early non-small cell lung cancer patients.

Methods: Patients with newly diagnosed, pathologically confirmed non-small cell lung cancer were entered into this blinded cohort study. The activity of cyclin-dependent kinases was determined in 171 samples by the C2P® assay, and the results were subjected to statistical analysis with recurrence or death as a clinical outcome.

Results: The Cox proportional hazards model revealed that the activity of cyclin-dependent kinase 1, but not 2, was a predictor of recurrence, independent of sex, age, and stage. By contrast, cyclin-dependent kinase 2 activity was a predictor of death, independent of sex and stage.

Conclusion: This study suggested the possible clinical use of cyclin-dependent kinase 1 as a predictor of recurrence and cyclin-dependent kinase 2 as a predictor of overall survival in early-stage non-small cell lung cancer. Thus, a combination of activity of cyclin-dependent kinases 1 and 2 is useful in decision-making regarding treatment strategies for non-small cell lung cancer after surgery.

Keywords: Non-small cell lung cancer, Cyclin-dependent kinase, Surgical resection, Recurrence, Mortality

Background
Lung cancer is one of the leading causes of cancer death worldwide. Despite recent advances in cancer treatment, the prognosis of lung cancer is not sufficient compared with that of other solid organ tumors [1]. Even after complete surgical resection, the 5-year survival of early-stage non-small cell lung cancer (NSCLC) patients is only approximately 65% [2-4]. This poor prognosis is due to the high recurrence after resection [5,6], which supports the presence of occult metastases. The survival benefit of adjuvant platinum-based chemotherapy has been established in stage II–III NSCLC [7-9]; however, there is no data supporting the use of adjuvant treatments for stage IA NSCLC, and the use of adjuvant chemotherapy for stage IB NSCLC is controversial [10]. Recently developed molecular biomarkers predict only non-squamous NSCLC [11,12], and no biomarkers for squamous cell carcinoma (SCC) have reached the validation stage. Therefore, in the setting of lung cancer, the identification of biomarkers for predicting the outcome after surgery and selecting patients who could benefit from adjuvant chemotherapy is crucial.

* Correspondence: hkubo@med.tohoku.ac.jp
1Department of Advanced Preventive Medicine for Infectious Disease, Tohoku University Graduate School of Medicine, 2-1 Seiryoumachi, Aobaku, Sendai 980-8575, Japan
Full list of author information is available at the end of the article

© 2014 Kubo et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
A breakdown in the cell cycle machinery induces the uncontrolled proliferation of tumors. This process is initiated by a variety of molecules in a cascade that activates the cyclin-dependent kinases (CDKs), which play a role in the progression of the cell cycle. On the molecular level, the activity of CDKs is regulated by subunits known as cyclins, and by phosphorylation and dephosphorylation of key residues, for example, Thr14, Tyr15, and Thr160 in CDK2 [13]. A series of pathological investigations of the molecules that stimulate CDKs have clearly demonstrated their clinical significance for cancer diagnosis and treatment. For example, clinical evidence has indicated that the overexpression of cyclin E and cyclin B, which bind to and activate CDK2 and CDK1, respectively, correlates with tumorigenesis, prognosis, and sensitivity to chemotherapy in a variety of malignancies, as does the inactivation of CDK inhibitors, such as p21WAF1 and p27Kip1 [14-20]. The pairing between the CDK and cyclin isotypes is specific. However, the amount of cyclin protein did not correspond perfectly with CDK activity in our investigation (data not shown). Similar results regarding the association between cyclin E and the activity of its associated kinase were reported by another group [21]. Therefore, we hypothesized that the direct measurement of CDK activity might produce relevant clinical indications for cancer diagnosis and treatment. Previously, we reported that the CDK-based risk score (C2P® assay, Sysmex, Japan) predicted the risk of distant recurrence in early breast cancer patients [22]. The C2P® assay is determined using a combination of the specific activity of CDK1 (CDK1SA) and CDK2 (CDK2SA). The feasibility of this assay was confirmed in a cohort study in Caucasian breast cancer patients [23] and in colon cancer patients [24]. CDKSA levels were significantly associated with a pathologically complete response (pCR) after weekly administration of paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in breast cancer [25].

In lung cancer, many cell cycle-related molecules have been reported to be correlated with prognosis [26-31]. Here, we investigated whether the activity of CDK1 and CDK2 could predict the recurrence of NSCLC or the death of stage I and II NSCLC patients.

**Methods**

**Study design**

This blinded cohort study was approved by the local ethics committees of Tohoku University and Hyogo Cancer Centre. All patients provided written informed consent. A total of 213 patients who were newly diagnosed with pathologically confirmed NSCLC at the two centers were enrolled in this study. The eligibility criteria were as follows: SCC, adenocarcinoma, and stage I–II disease. All patients underwent complete resection, and none received adjuvant or neoadjuvant chemotherapy. CDK1SA and CDK2SA were determined in 171 samples using a C2P® assay (Sysmex, Kobe, Japan), and the results were subjected to statistical analysis to evaluate recurrence or death as a clinical outcome. Tumor tissue was dissected immediately after resection, snap-frozen and stored at −80°C at each facility. Then, the samples were sent to the Sysmex Corporation (Kobe, Japan) and subjected to the C2P® assay. Tissues with extreme blood contamination were excluded from this study, because the expression level of CDKs is underestimated in the presence of more than 1600 ng/μL of hemoglobin. The histologic types were centrally reviewed at Tohoku University.

**Patients**

A total of 213 patients with primary NSCLC who had undergone surgery between July 2000 and September 2009 were recruited for this study. Twenty-four cases were excluded due to extreme blood contamination of the samples. C2P® assay measurements were performed on 189 frozen samples; in 18 cases, the CDK expression levels were below the detection threshold, and these samples were excluded from the analysis. Finally, 171 cases were subjected to statistical analyses, including 53 SCCs and 118 adenocarcinomas. The median follow-up period was 43.9 months (70–2820 days).

**Measurement of CDK1SA and CDK2SA**

The C2P® assay [15,22] was used to measure the specific activity of CDKs. In brief, lysates of freshly frozen samples were applied to the wells of a 96-well PVDF filter plate (Millipore, Billerica, MD, USA). The expression of CDK protein was detected quantitatively by paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in breast cancer [25].

Measurement of CDK1SA and CDK2SA

In lung cancer, many cell cycle-related molecules have been reported to be correlated with prognosis [26-31]. Here, we investigated whether the activity of CDK1 and CDK2 could predict the recurrence of NSCLC or the death of stage I and II NSCLC patients.

**Methods**

**Study design**

This blinded cohort study was approved by the local ethics committees of Tohoku University and Hyogo Cancer Centre. All patients provided written informed consent. A total of 213 patients who were newly diagnosed with pathologically confirmed NSCLC at the two centers were enrolled in this study. The eligibility criteria were as follows: SCC, adenocarcinoma, and stage I–II disease. All patients underwent complete resection, and none received adjuvant or neoadjuvant chemotherapy. CDK1SA and CDK2SA were determined in 171 samples using a C2P® assay (Sysmex, Kobe, Japan), and the results were subjected to statistical analysis to evaluate recurrence or death as a clinical outcome. Tumor tissue was dissected immediately after resection, snap-frozen and stored at −80°C at each facility. Then, the samples were sent to the Sysmex Corporation (Kobe, Japan) and subjected to the C2P® assay. Tissues with extreme blood contamination were excluded from this study, because the expression level of CDKs is underestimated in the presence of more than 1600 ng/μL of hemoglobin. The histologic types were centrally reviewed at Tohoku University.

**Patients**

A total of 213 patients with primary NSCLC who had undergone surgery between July 2000 and September 2009 were recruited for this study. Twenty-four cases were excluded due to extreme blood contamination of the samples. C2P® assay measurements were performed on 189 frozen samples; in 18 cases, the CDK expression levels were below the detection threshold, and these samples were excluded from the analysis. Finally, 171 cases were subjected to statistical analyses, including 53 SCCs and 118 adenocarcinomas. The median follow-up period was 43.9 months (70–2820 days).

**Measurement of CDK1SA and CDK2SA**

The C2P® assay [15,22] was used to measure the specific activity of CDKs. In brief, lysates of freshly frozen samples were applied to the wells of a 96-well PVDF filter plate (Millipore, Billerica, MD, USA). The expression of CDK protein was detected quantitatively by sequential reactions with primary anti-CDK antibodies, biotinylated anti-rabbit antibodies and fluorescein-labeled streptavidin. To measure the kinase activity, CDK molecules were immunoprecipitated from the lysate using protein beads. CDK SA activity (maU/eU) was calculated as CDK activity units (maU/μL lysate, respectively). When the expression level was lower than the detection limit of the assay, the case was excluded from the analysis. The detection limits for the expression level of CDK1 and CDK2 are 0.1 and 0.003 eU/μL lysate, respectively.

**Statistical analysis**

Recurrence-free survival (RFS) was calculated from the date of surgery to the date of first local or distant recurrence; patients who were alive without recurrence at the time of data collection and those who died without any evidence of the disease on the date of death were censored. The overall
survival (OS) was calculated from the date of surgery to the date of death; patients who were alive were censored.

The data were analyzed using MedCalc version 12.3 (MedCalc Software, Ostend, Belgium), and survival between the groups was compared using the Kaplan-Meier method and an unstratified Cox proportional hazards model or the log-rank test. Correlation tables were analyzed using the chi-square test. Receiver operating characteristic (ROC) curves and the corresponding area under the curve (AUC) for the compared models were computed to simulate predictive accuracy.

Possible prognostic variables that were analyzed in this study included age (>70 vs <70 years), sex (male or female), tumor size (>3 vs ≤3 cm), nodal status (negative or positive), pathological stage (≥IB vs IA), histological type (SCC vs adenocarcinoma), CDK1SA (≥12.6 vs <12.6) and CDK2SA (≥222 vs <222). A value of \( p < 0.05 \) was considered significant.

**Results**

We obtained fresh-frozen samples from 213 cases from two centers: Tohoku University Hospital and Hyogo Cancer Centre. Twenty-four cases were excluded due to extreme blood contamination. The C2P assay was performed on 189 frozen samples (see Additional file 1); in 18 cases, the CDK expression levels were below the detection threshold, and these cases were excluded from the analysis (assay success rate =90%). Finally, 171 samples were subjected to statistical analysis (Figure 1). The patients who were analyzed included 106 (62%) males and 65 (38%) females, with a median age of 70 years (38–86) (Table 1). The median tumor size was 3.0 cm (0.9–10.0). A total of 150 cases (88%) were node-negative, and 21 cases (12%) were positive. The histologic type was centrally confirmed as SCC in 118 cases (69%), or death as a clinical outcome (Tables 3 and 4). Univariate analysis for recurrence revealed that sex (HR 2.53, 95% CI 1.16–5.52; \( p = 0.0200 \)), age (HR 2.80, 95% CI 1.36–5.77; \( p = 0.0054 \)), tumor size (HR 3.04, 95% CI 1.35–6.77; \( p = 0.0025 \)), stage (HR 2.54, 95% CI 1.30–4.99; \( p = 0.0070 \)) and CDK1SA (HR 2.26, 95% CI 1.16–4.43; \( p = 0.0177 \)) were statistically significant (\( p < 0.05 \)). Age, stage and CDK1SA remained significant by multivariate analysis for recurrence (Table 3, age

---

**Figure 1 Flow chart of patient enrolment and reasons for exclusion.**

213 primary stage I or II NSCLC patients underwent radical surgery without adjuvant chemotherapy between 2000 and 2009

- 42 patients
- 24 specimens with extreme blood contamination
- 18 specimens with no detectable CDK expression

171 primary stage I or II NSCLC patients were analyzed in this study
### Table 1 Clinical and pathological characteristics of patients

|                          | Total collective | Tohoku University | Hyogo Cancer Centre |
|--------------------------|------------------|------------------|--------------------|
| Frozen blocks available  | 213              | 111              | 102                |
| Successful CDK assay     | 171              | 90               | 81                 |
| Sex                      |                  |                  |                    |
| Male                     | 106 (62%)        | 57 (63%)         | 49 (60%)           |
| Female                   | 65 (38%)         | 33 (37%)         | 32 (40%)           |
| Age                      |                  |                  |                    |
| < 70 years               | 83 (49%)         | 43 (48%)         | 40 (49%)           |
| ≥ 70 years               | 88 (52%)         | 47 (52%)         | 41 (51%)           |
| Tumor size               |                  |                  |                    |
| ≤ 3 cm                   | 95 (56%)         | 52 (58%)         | 43 (53%)           |
| > 3 cm                   | 76 (44%)         | 38 (42%)         | 38 (47%)           |
| pN                       |                  |                  |                    |
| −                        | 150 (88%)        | 83 (92%)         | 67 (83%)           |
| +                        | 21 (12%)         | 7 (8%)           | 14 (17%)           |
| Stage                    |                  |                  |                    |
| IA                       | 89 (52%)         | 48 (53%)         | 41 (51%)           |
| IB                       | 45 (26%)         | 28 (31%)         | 17 (21%)           |
| IIA                      | 31 (18%)         | 11 (12%)         | 20 (25%)           |
| IIB                      | 6 (4%)           | 3 (3%)           | 3 (4%)             |
| Histology                |                  |                  |                    |
| Adenocarcinoma           | 118 (69%)        | 58 (64%)         | 60 (74%)           |
| SCC                      | 53 (31%)         | 32 (36%)         | 21 (26%)           |
| Recurrence               |                  |                  |                    |
| None                     | 134 (78%)        | 81 (90%)         | 53 (65%)           |
| Local                    | 14 (8%)          | 3 (3%)           | 11 (14%)           |
| Distant                  | 23 (14%)         | 6 (7%)           | 17 (21%)           |
| Survival information     |                  |                  |                    |
| Alive                    | 133 (78%)        | 75 (83%)         | 58 (72%)           |
| Dead                     | 38 (22%)         | 15 (17%)         | 23 (28%)           |

### Table 2 Association between CDK-based risk groups and clinicopathological parameters

|                  | CDK1SA (cut-off = 12.6) |                  | CDK2SA (cut-off = 222) |                  |
|------------------|--------------------------|------------------|--------------------------|------------------|
|                  | Low  | High | Significance (Chi-square) | Low  | High | Significance (Chi-square) |
| Sex              |      |      |                          |      |      |                          |
| Male             | 57   | 49   |                          | 76   | 30   |                          |
| Female           | 35   | 30   |                          | 55   | 10   |                          |
| Age              |      |      |                          |      |      |                          |
| < 70 years       | 43   | 40   |                          | 66   | 17   |                          |
| ≥ 70 years       | 49   | 39   |                          | 65   | 23   |                          |
| Tumor size       |      |      |                          |      |      |                          |
| ≤ 3 cm           | 55   | 40   |                          | 76   | 19   |                          |
| > 3 cm           | 37   | 39   |                          | 55   | 21   |                          |
| pN               |      |      |                          |      |      |                          |
| −                | 85   | 65   |                          | 118  | 32   |                          |
| +                | 7    | 14   |                          | 13   | 8    |                          |
| Stage            |      |      |                          |      |      |                          |
| IA               | 53   | 36   |                          | 73   | 16   |                          |
| IB               | 25   | 20   |                          | 37   | 8    |                          |
| IIA              | 12   | 19   |                          | 18   | 13   |                          |
| IIB              | 2    | 4    |                          | 3    | 3    |                          |
| Histology        |      |      |                          |      |      |                          |
| Adenocarcinoma   | 64   | 54   |                          | 101  | 17   |                          |
| SCC              | 28   | 25   |                          | 30   | 23   |                          |
| Facility         |      |      |                          |      |      |                          |
| Tohoku Univ      | 53   | 37   |                          | 72   | 18   |                          |
| Hyogo CC         | 39   | 42   |                          | 59   | 22   |                          |
HR 3.06, \( p = 0.0028 \); stage HR 2.16, \( p = 0.0306 \); CDK1SA HR 2.25, \( p = 0.0195 \). Even in the subgroup of 134 patients with stage IA and IB disease, CDK1SA but not CDK2SA had the prognostic power (Figures 3A and B, CDK1SA HR 2.56, \( p = 0.0273 \); CDK2SA HR 1.18, \( p = 0.7375 \)). The Cox regression analysis revealed that CDK1SA was an independent predictor of recurrence (Table 5, HR 2.57, 95% CI 1.08–6.09; \( p = 0.0335 \)).

Regarding CDK2SA, which had a cut-off value of 222 maU/eU, the cases were classified as low CDK2SA (77%, 131 cases) or high CDK2SA (23%, 40 cases). Patients with low CDK2SA tumors showed significantly higher OS than those with high CDK2SA tumors based on a log-rank test (Figure 2D, HR 2.49, 95% CI 1.19–5.21; \( p = 0.0033 \)).

According to the univariate analysis for death, CDK2SA (HR 2.56, 95% CI 1.34–4.87; \( p = 0.0045 \)) was statistically significant along with sex (HR 5.51, 95% CI 1.96–15.5; \( p = 0.0013 \)), tumor size (HR 2.36, 95% CI 1.22–4.55; \( p = 0.0111 \)), pathological lymph node status (HR 2.82, 95% CI 1.34–5.96; \( p = 0.0069 \)) and stage (HR 2.75, 95% CI 1.39–5.44; \( p = 0.0039 \)). By multivariate analysis, sex, stage, and CDK2SA remained significant (sex HR 4.14, \( p = 0.0081 \); stage HR 2.09, \( p = 0.0421 \); CDK2SA HR 1.97, \( p = 0.0500 \)).

### Table 3 Cox proportional hazards models for recurrence

|                         | Univariate analysis | Multivariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|-----------------------|
|                         | HR (95% CI)         | \( p \) value         | HR (95% CI)           | \( p \) value         | HR (95% CI)         | \( p \) value         |
| Sex Male                | 2.53 (1.16–5.52)    | 0.0200                | 1.99 (0.90–4.42)      | 0.0913                | 2.00 (0.91–4.40)    | 0.0876                |
| Age ≥ 70 years          | 2.80 (1.36–5.77)    | 0.0054                | 3.06 (1.48–6.34)      | 0.0028                | 2.79 (1.35–5.75)    | 0.0056                |
| Tumor size > 3 cm       | 1.99 (1.04–3.81)    | 0.0380                |                       |                       |                       |                       |
| pN +                    | 3.20 (1.51–6.77)    | 0.0025                |                       |                       |                       |                       |
| Stage ≥ IB              | 2.54 (1.30–4.99)    | 0.0070                | 2.16 (1.08–4.31)      | 0.0306                | 2.23 (1.13–4.43)    | 0.0222                |
| Histology SCC           | 1.23 (0.62–2.44)    | 0.5567                |                       |                       |                       |                       |
| CDK1SA ≥ 12.6           | 2.26 (1.16–4.43)    | 0.0177                | 2.25 (1.14–4.42)      | 0.0195                |                       |                       |
| CDK2SA ≥ 222            | 1.82 (0.93–3.56)    | 0.0837                |                       |                       | 1.53 (0.79–3.01)    | 0.2165                |
Subanalysis by histology revealed that the predictive value of CDK1SA for recurrence was stronger in adenocarcinoma than in SCC (Figure 4A and B, adenocarcinoma HR 2.26, \( p = 0.0439 \); SCC HR 2.09, \( p = 0.2182 \)). On the contrary, in the SCC cases, the Cox regression analysis for recurrence revealed that only CDK2SA was statistically significant (Figure 4C and D, Table 6, HR 3.86, 95% CI 1.05–14.2; \( p = 0.0428 \)). In the distribution of 35 recurrent cases on a scatter diagram with logarithmic scales according to CDK1SA and CDK2SA, we observed that the distribution of the non-survivors slightly shifted to the higher CDKSAs area (data not shown). This observation let us to perform Kaplan-Meier analyses, and it was found that the prognostic power of CDK2SA, but not of CDK1SA (Figure 5A), was significant in 35 patients who were treated with chemotherapy after recurrence (Figure 5B, HR for death 4.30, 95% CI 1.56–11.8; \( p < 0.0001 \)).

**Discussion**

In this study, we demonstrated that CDK1SA and CDK2SA could identify individuals that were at high risk for recurrence and death among early-stage NSCLC patients after surgical resection. Even with complete resection, the prognosis of early-stage NSCLC is not good due to local and distant recurrence [6], and it remains unclear which biomarkers are clinically useful for predicting recurrence, although some single molecules and gene signatures of non-squamous cell carcinomas are being validated in a large number of cohorts [11,32]. Previously, cyclin expression and prognosis were reported to be correlated in lung cancer patients [33]; however, this is the first study revealing that CDK activity is a promising predictor for early-stage NSCLCs. Furthermore, CDK1SA and CDK2SA are the first biomarkers that can be used to predict the prognosis of both adenocarcinoma and SCC. Because CDKs are the targets of new anti-cancer drugs and the development of many CDK inhibitors is underway [34], this study will provide a basis for future personalized medicine using CDK inhibitors in NSCLC patients.

CDK1SA and CDK2SA have different implications in lung cancer. CDK1SA predicted recurrence after surgery, whereas CDK2SA predicted the overall survival of stage I and II NSCLC patients (Figure 2). Sub-analysis of 134 patients with stage IA and IB disease showed that CDK1SA was an independent predictor only for recurrence, but the power of prediction was much better than conventional criteria such as tumor size and stage (Figure 3 and Table 5). The clinical relevance of

**Table 4 Cox proportional hazards models for death**

|                          | Univariate analysis |                           |                           |
|--------------------------|---------------------|---------------------------|---------------------------|
|                          | HR (95% CI)         | \( p \) value             | HR (95% CI)               |
|                          |                     |                           | \( p \) value             |
|                          |                     |                           | HR (95% CI)               |
|                          |                     |                           | \( p \) value             |
| Sex Male                 | 5.51 (1.96–15.46)   | 0.0013                    | 4.29 (1.50–12.30)         |
| Age ≥ 70 years           | 1.24 (0.66–2.35)    | 0.5088                    | 4.14 (1.45–11.78)         |
| Tumor size > 3 cm        | 2.36 (1.22–4.55)    | 0.0111                    |                           |
| pN +                     | 2.82 (1.34–5.96)    | 0.0069                    |                           |
| Stage ≥ IB               | 2.75 (1.39–5.44)    | 0.0039                    | 1.79 (0.87–3.71)          |
| Histology SCC            | 2.49 (1.31–4.72)    | 0.0053                    | 1.53 (0.78–2.97)          |
| CDK1SA ≥ 12.6            | 1.74 (0.91–3.32)    | 0.0962                    | 1.53 (0.79–2.97)          |
| CDK2SA ≥ 222             | 2.56 (1.34–3.87)    | 0.0045                    | 1.97 (1.00–3.87)          |

**Figure 3** Analysis of recurrence by risk category in stage I NSCLC. (A) Recurrence-free survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. (B) Recurrence-free survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.
CDK1SA as a marker for recurrence prediction is in agreement with the conclusion of the colon study [24]. In this colon study, CDK1SA was significantly elevated in microsatellite-stable tumors. Because most of colorectal cancers with stable microsatellites demonstrate chromosomal instability [35], CDK1SA may have value as a marker of genomic instability. Genomic instability has been reported to predict clinical outcomes in multiple cancer types, including lung cancer [36-39]; therefore, prediction of recurrence demonstrated in this study may reflect the genomic instability of the tumors. According to sub-analysis by histology, the predictive value of CDK1SA for recurrence was greater in adenocarcinoma than in SCC (Figure 4A and B). Since adenocarcinoma is the most common histologic type of colon cancer, there is a similarity in the role of CDK1SA in colon and lung adenocarcinoma. Interestingly, Cox regression analysis for recurrence revealed that CDK2SA expression was statistically significant in SCC but not in adenocarcinoma (Figure 4C, D and Table 6). This result suggests that CDK1 and CDK2 have different roles in adenocarcinoma and SCC.

In contrast to CDK1SA, CDK2SA predicted overall survival after surgery. This finding may be related to the

Table 5 Cox proportional hazards models for recurrence (Stage I)

|            | Univariate analysis |          |          |
|------------|---------------------|----------|----------|
|            | HR (95% CI)         | p value  |          |
| Sex Male   | 2.17 (0.85–5.53)    | 0.1050   |          |
| Age ≥ 70 years | 1.79 (0.75–4.24)    | 0.1908   |          |
| Tumor size > 3 cm | 1.41 (0.59–3.35)    | 0.4413   |          |
| Stage ≥ IB | 1.67 (0.71–3.90)    | 0.2390   |          |
| Histology SCC | 1.10 (0.41–2.96)    | 0.8568   |          |
| CDK1SA ≥ 12.6 | 2.57 (1.08–6.09)    | 0.0335   |          |
| CDK2SA ≥ 222 | 1.19 (0.44–3.21)    | 0.7381   |          |

Table 6 Cox proportional hazards models for recurrence (SCC)

|            | Univariate analysis |          |          |
|------------|---------------------|----------|----------|
|            | HR (95% CI)         | p value  |          |
| Sex Male   | NA                  |          |          |
| Age ≥ 70 years | 1.48 (0.47–4.65)    | 0.5014   |          |
| Tumor size > 3 cm | 1.77 (0.48–6.52)    | 0.3905   |          |
| pN +       | 1.94 (0.59–6.44)    | 0.2793   |          |
| Stage ≥ IB | 2.42 (0.54–10.99)   | 0.2530   |          |
| CDK1SA ≥ 12.6 | 2.09 (0.63–6.91)    | 0.2286   |          |
| CDK2SA ≥ 222 | 3.86 (1.05–14.17)   | 0.0428   |          |

NA, not analyzed due to bias (89% of SCC patients were male).

Figure 4 Analysis of recurrence by risk category in adenocarcinoma (A) (C) and SCC (B) (D). (A)(B) Recurrence-free survival according to CDK1SA-based risk with a cut-off value of 12.6 maU/eU. (C)(D) Recurrence-free survival according to CDK2SA-based risk with a cut-off value of 222 maU/eU.
chemo-sensitivity of the patients. Kaplan-Meier analysis indicated that the prognostic power of CDK2SA was significant in patients treated primarily with platinum-based chemotherapy after recurrence (Figure 5), suggesting that CDK2SA can predict platinum sensitivity/resistance. A similar trend was observed in our ovary study: tumors with high CDK2SA were more platinum-resistant in patients who underwent incomplete resection and subsequent platinum-based chemotherapy (unpublished data). The ability of cyclin E-associated kinase activity to predict the response to platinum-based chemotherapy in ovarian cancer patients was also reported by another group [21]. In addition, inhibition of CDK2, but not CDK1, induced growth arrest in lung cancer cell lines through anaphase catastrophe [40]. Taken together, these data indicate that CDK2 would be a good target for lung cancer treatment, and the measurement of CDK2SA could be useful for identifying patients who would receive the full benefit of CDK2 inhibitors.

A limitation of this study was that the number of cases in the sub-analysis for the outcome after platinum-based chemotherapy was low; however, the significant difference was quite clear (Figure 5). Prospective studies should be performed to clarify the predictive capacity of CDK2SA in platinum sensitivity/resistance in early-stage NSCLC patients after surgical resection.

In summary, this study suggested the possible clinical use of CDK1SA for recurrence prediction and CDK2SA for the prognosis of stage I and II NSCLC. Moreover, CDK2SA might be a predictor of platinum-based chemotherapy sensitivity/resistance. To the best of our knowledge, this is the first report that suggests a relationship between chemosensitivity and CDK activity in lung cancer. Thus, a combination of CDK1SA and CDK2SA might be helpful in decision-making regarding NSCLC treatment strategies.

Conclusions
CDK1SA is a predictor of recurrence and CDK2SA is a predictor of overall survival in early-stage NSCLC after surgery.

Additional file

Additional file 1: Distribution of lung tumors according to CDK1SA and CDK2SA. Adenocarcinoma cases and SCC cases are plotted on a scatter diagram with logarithmic scales according to CDK1SA and CDK2SA. Black square: the specific activity was defined as 0.5 when the activity of CDK is lower than the detection limit of the assay. The detection limits for the activity of CDK1 and CDK2 are 10 and 2 maU/μL lysate, respectively.

Abbreviations
NSCLC: Non-small cell lung cancer; SCC: Squamous cell carcinoma; CDKs: Cyclin-dependent kinases; CDK1SA: Specific activity of CDK1; CDK2SA: Specific activity of CDK2.

Competing interests
This study was supported by the Sysmex Corporation (Kobe, Japan). The sponsor was involved in the study design as well as the data collection, analysis, and interpretation. ST and TM of Sysmex Corporation had access to the full raw data. HI was previously affiliated with the Sysmex Corporation, was authorized to access to the primary raw data, and performed the initial analysis of this study. However, HI is now affiliated with the other company, Nittobo Medical Co. Ltd., which has no relation with the Sysmex Corporation; and has no access to the full raw data. Otherwise, the authors declare that they have no competing interests.

Authors’ contributions
HK: Conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; TS: Collection and assembly of data, pathological analysis and interpretation, final approval of manuscript; TM and ST: Collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; HI: Collection and assembly of data, data analysis and interpretation, final approval of manuscript; KU, SS, MY, and TK: Provision of study material and patients, obtain informed consent from the patients, final approval of manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported by Sysmex Corporation, Kobe, Japan.
14. Strauss GM, Hendron JE, Maddau MA, Johnstone DW, Johnson EA, Harpole DH, Gillenwater HH, Watson DM, Sugarbaker DJ, Schilsky RL, Vokes EE, Green MR: Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Treatment. J Clin Oncol 2007, 25:5506–5518.

15. Kiatkarnjanakul P, Naisiri S, Srisurapanont M, Jitpichet C, Laksanakanok S, Suwanprasert S, Thaweesuk S, Srijongkroo P, Srisurapanont S: Expression of cyclin D1 and p16 in non-small cell lung cancer patients: correlation with clinical features. J Med Assoc Thai 2014, 97:432–437.

16. Jang SY, Lee HJ, Lee HN, Park JW, Kim HJ, Lee SY, Park SJ, Lim JY, Kim HD: Expression of p16 and cyclin D1 in non-small cell lung cancer patients. J Cancer Res Ther 2012, 8:382–385.

17. Sjostrom J, Blomqvist C, Heikkila K, Boguslawski K, Raisanen-Sokolowski A, Bengtsson NO, Mjaaland I, Malström P, Ostendarp B, Bergh J, Wist E, Valverde V, Sakiela E: Predictive value of p133 and p21 and miR 1 for chemotherapy response in advanced breast cancer. Clin Cancer Res 2003, 9:3110–3116.

18. Sato Y, Nagai Y, Takahashi T, Takahashi M, Naito M, Yamaguchi H, Ishii K, Ito Y, Kamiya J, Ohno Y, Minamisawa H, Hino K, Tsuruda K: Expression of cyclin D1 in non-small cell lung cancer patients: correlation with clinicopathological features. J Cancer Res Ther 2012, 8:389–392.

19. Suzuki T, Urano T, Miki Y, Moriya T, Akahira J, Ishida T, Hone K, Inoue S, Sawai H: Nuclear cycle B1 in human breast carcinoma as a potent prognostic factor. Cancer Sci 2007, 98:644–651.

20. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I: Cyclin D2 Overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Ann J Pathol 2005, 167:1095–1103.

21. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

22. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

23. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

24. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

25. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

26. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

27. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

28. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

29. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.

30. Badiousee M, Cattolico O, Taliani S, Gatti M, Pavesi G, Porter S, De Marzo A, Balducci L, Marchisio P, Gattuso P, Biondi A: cyclin D2 overexpression in prostate cancer: correlation with clinicopathological features. J Cancer Res Ther 2010, 6:378–383.
31. Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H: The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol 2004, 15:252–256.
32. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol 2012, 9:144–155.
33. Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM: Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005, 11:3974–3986.
34. Schwartz GK, Shah MA: Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005, 23:9408–9421.
35. Walther A, Johnstone E, Swanton C, Airdigley R, Tomlinson I, Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009, 9:489–499.
36. Albertson DG, Collins C, McCormick F, Gray JW: Chromosome aberrations in solid tumors. Nat Genet 2003, 34:369–376.
37. Carter SL, Ekland AC, Kohane IS, Harris LN, Szallasi Z: A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006, 38:1043–1048.
38. Mettu RK, Wan YW, Habermann JK, Ried T, Guo NL: A 12-gene genomic instability signature predicts clinical outcomes in multiple cancer types. Int J Biol Markers 2010, 25:219–228.
39. Nakamura H, Saji H, Idiris A, Kawasaki N, Hosaka M, Ogata A, Saijo T, Kato H: Chromosomal instability detected by fluorescence in situ hybridization in surgical specimens of non-small cell lung cancer is associated with poor survival. Clin Cancer Res 2003, 9:2294–2299.
40. Galimberti F, Thompson SL, Liu X, Li H, Memoli V, Green SR, DiRenzo J, Greninger P, Sharma SV, Settleman J, Compton DA, Dmitrovsky E: Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res 2010, 16:109–120.

doi:10.1186/1471-2407-14-755
Cite this article as: Kubo et al.: Cyclin-dependent kinase-specific activity predicts the prognosis of stage I and stage II non-small cell lung cancer. BMC Cancer 2014 14:755.